Efficacy and safety of conbercept for choroidal neovascularization secondary to chronic central serous chorioretinopathy

Auhtors: Mao Jianbo,  Zhang Caiyun,  Shen Lijun,  Lao Jimeng,  Shao Yirun,  Wu Hanfei,  Chen Yiqi,  Tao Jiwei

DOI: 10.3760/cma.j.cn115989-20201104-00742
Published 2021-01-10
Cite as Chin J Exp Ophthalmol, 2021,39(01): 42-46.

Abstract

Objective

To evaluate the efficacy and safety of conbercept in patients with choroidal neovascularization secondary to chronic central serous chorioretinopathy (CSC-CNV).

Methods

A retrospective case study was performed.The medical records of 13 patients (14 eyes) diagnosed as chronic CSC-CNV in Hangzhou Branch of Eye Hospital of Wenzhou Medical University from September 2015 to January 2018 were collected.All the study eyes received intravitreal injection of conbercept (0.05 ml/0.5 mg) under one intravitreal injection and pro re nata (PRN) treatment.The best corrected visual acuity (BCVA) and central macular thickness (CMT) before initial injection and 1 week, 1 month, 2, 3 and 6 months after initial injection were measured and analyzed.This study followed the Declaration of Helsinki and written informed consent was obtained from each patient before initial injection.The study protocol was approved by the Ethics Committee of Hangzhou Branch of Eye Hospital of Wenzhou Medical University (No.2019-029-K-28).

Results

During the 6-month follow-up, the mean administration times was 1.93±0.83, and all the CNV secondary to CSC did not grow outside the retinal pigment epithelium layer.The BCVA values before initial injection and 1 week, 1 month, 2, 3 and 6 months after initial injection were 0.51±0.32, 0.43±0.34, 0.36±0.35, 0.31±0.28, 0.27±0.29 and 0.26±0.30, respectively, with a significant difference among different time points (F=21.225, P<0.05). The BCVA values at each time point after initial injection were significantly better than that before initial injection (all at P<0.05). The CMT values before initial injection and 1 week and 1 month, 2, 3, 6 months after initial injection were (299.07±132.90), (216.50±70.94), (203.00±61.87), (234.29±95.70), (194.21±46.46) and (207.43±55.46) μm, respectively, and the difference was statistically significant among different time points (F=3.768, P<0.05). The CMT values at each time point after initial injection were significantly better than that before initial injection (all at P<0.05). No severe treatment complications were observed during the follow-up period.

Conclusions

Intravitreal injection of conbercept is safe and can effectively reduce the CMT and improve BCVA of chronic CSC-CNV patients in the short term.

Key words:

Chronic central serous chorioretinopathy; Choroidal neovascularization; Conbercept; Best corrected visual acuity; Central macular thickness

Contributor Information

Mao Jianbo
Eye Hospital of Wenzhou Medical University, Hangzhou 310020, China
Zhang Caiyun
Eye Hospital of Wenzhou Medical University, Hangzhou 310020, China
Shen Lijun
Eye Hospital of Wenzhou Medical University, Hangzhou 310020, China
Lao Jimeng
Eye Hospital of Wenzhou Medical University, Hangzhou 310020, China
Shao Yirun
Eye Hospital of Wenzhou Medical University, Hangzhou 310020, China
Wu Hanfei
Eye Hospital of Wenzhou Medical University, Hangzhou 310020, China
Chen Yiqi
Eye Hospital of Wenzhou Medical University, Hangzhou 310020, China
Tao Jiwei
Eye Hospital of Wenzhou Medical University, Hangzhou 310020, China
(Read 13 times, 1 visits today)
Updated: January 26, 2021 — 6:12 am